Which Companies Will Be Acquired Before 2027? A Tactical List of Likely Targets

The M&A market is entering 2026 with real momentum, a direct carryover from a late-2025 surge in megadeals and AI-driven thematics. Confidence has improved as financing conditions stabilized, and buyers have grown more comfortable underwriting growth in a market shaped by artificial intelligence. This mix set the tone for a year where boards are expected to act faster and run tighter processes. The result is a K-shaped market structure, where deal value is expected to remain elevated even as overall volumes stay muted. Activity is increasingly concentrated in the largest transactions and among the best-capitalized buyers, with strength polarized toward a small number of markets and sectors.

This polarization is clearest in the technology-led deals that dominate the megadeal category. The catalyst here is strategic necessity. Buyers are prioritizing targets that unlock clear product expansion or control of critical infrastructure like data centers and security. In other words, the deals aren't about diversification for its own sake; they are about securing the specific assets needed to compete in the AI era. This creates a vulnerable subset of targets: companies that are well-capitalized, tech-led, and operate in sectors where organic growth is slow or impossible. These are the companies that strategic buyers can no longer afford to build from scratch.

The setup is particularly acute in two high-stakes areas. In biotech, the strategic imperative is to secure differentiated science before clinical proof becomes fully priced in. The recent Eli Lilly acquisition of Ventyx Biosciences for $1.2 billion is a textbook example, a bolt-on move to expand beyond blockbuster metabolic drugs into inflammation and immune-driven diseases. In technology and industrial sectors, the need is to control the physical infrastructure of AI. This explains the scale of deals in energy and power, where tech companies are investing directly in the enabling infrastructure. The bottom line is that the 2026 M&A catalyst is not a broad market rally. It is a targeted hunt for specific capabilities, creating a narrow window of opportunity for well-positioned, tech-led targets.

Specific Categories and Examples: The Likely Targets

The strategic hunt is narrowing, and the January activity shows the pattern. M&A in pharma was active but skewed toward mid-size, bolt-on deals rather than blockbuster takeovers. The standout was GSK's $2.2 billion acquisition of RAPT Therapeutics, a move to bolster its pipeline in inflammatory and immunologic diseases. This fits the K-shaped dynamic: buyers are targeting specific, high-value assets to fill strategic gaps, not making broad diversification plays.

Nowhere is this more evident than in the obesity biotech sector, which has become a hotbed for M&A. The recent bidding war for Metsera, where Pfizer offered $4.9 billion and Novo Nordisk made a surprise return, sent a clear signal. It demonstrated that Big Pharma is willing to pay a premium for differentiated science in this crowded space. The reaction wasn't just about Metsera; it was a preview of the competitive intensity to come for any company with a next-generation weight-loss asset.

Targets in this environment are often companies with strong, niche pipelines or technologies that are hard to build organically. Eli Lilly's bid to acquire clinical-stage Ventyx Biosciences is a textbook case. Ventyx's focus on inflammatory diseases complements Lilly's own metabolic franchise, offering a path to expand beyond its blockbuster drugs. Similarly, analysts are now pointing to peers like Abivax, with its first-in-class oral therapy for ulcerative colitis, as a potential take-out darling. The appeal is the same: a derisked, novel mechanism that addresses unmet needs and cannot be easily replicated.

The bottom line is that the 2026 M&A catalyst is creating a narrow list of likely targets. These are companies operating in high-stakes therapeutic areas-obesity, inflammation, neuropsychiatry-with proprietary science that fits a strategic buyer's portfolio. The January deals and the Metsera bidding war have set the precedent: when the right fit emerges, the firepower is there to act.

Immediate Catalysts and Timeline: H1 vs. H2 2026

The 2026 M&A catalyst is already in motion, but the path to a deal is rarely a straight line. For investors watching for the next acquisition, the timeline is split between near-term catalysts and longer-term uncertainties. The first half of the year is where the most concrete moves are likely to happen, while the second half introduces more friction.

The most immediate pressure point is boardroom activism. In 2025, shareholder advisory campaigns accelerated alongside the broader dealmaking surge. This trend is expected to continue, with activists using proxy fights and public campaigns to force companies into strategic options, including a sale. When a board faces mounting pressure from influential shareholders, the calculus for a deal changes. It becomes a faster, more defensive option to unlock value, rather than a slow, organic strategy. This dynamic can be a powerful catalyst for a company to enter the market sooner rather than later.

For the market, the primary resolution source for any deal is an official announcement. This makes credible reporting a key early signal. When a major transaction is in play, the first public confirmation often comes from a credible news outlet, not the company itself. Analysts and traders watch for these reports as a leading indicator. The setup is clear: a company under activist pressure, combined with credible rumors of a bid, creates a high-probability window for an announcement in the first half of the year.

Yet even with momentum, regulatory review remains a key uncertainty. The recent history of Netflix's amended offer for Warner Bros. Discovery is a case in point. The deal faced a lengthy and complex approval process, creating significant delay and risk. This serves as a reminder that a deal can be announced and still fail to close. For targets in sectors like tech, media, or healthcare, where antitrust scrutiny is high, the path from announcement to completion can stretch well into the second half. The bottom line is that while the catalysts are building, the timeline for a final, completed deal is often longer than the initial announcement suggests.

Risk Factors and What to Watch

The bullish setup for 2026 M&A is clear, but it faces real roadblocks. The primary near-term constraint is the sheer scale of investment required to build the AI infrastructure that is driving the dealmaking. The multitrillion-dollar capital expenditure supercycle for data centers and energy is diverting cash and attention away from acquisitions. For now, this spending spree may temper M&A activity as companies prioritize internal build-outs over external purchases.

Yet this spending is also the seed for the next wave. The AI capital expenditure supercycle is setting up a longer-term innovation supercycle. Once the foundational infrastructure is in place, the focus will shift to acquiring the software, data, and specialized capabilities to power the next generation of products. This creates a two-phase dynamic: a short-term pause for capital allocation, followed by a potential surge in dealmaking as companies seek to commercialize their AI investments.

Financing remains a key enabler. Optimism is supported by the availability of capital, with private credit playing an increasingly important role in acquisition finance. This provides a crucial alternative to traditional bank debt, allowing deals to close even if broader credit markets tighten. The trend toward more flexible funding structures is a positive for deal execution.

The main risks to the thesis are external. Geopolitical tensions or a sudden tightening of credit markets could temper the optimism that is fueling the current wave. These factors could slow deal momentum, especially for cross-border transactions or in sensitive sectors. Regulators are also a watchpoint, with a more proactive stance on technology deals likely to increase scrutiny and the risk of conditions or blocks.

For investors, the key watchpoints are the interplay between these forces. Monitor whether the AI capex spending begins to ease, signaling a shift from build to buy. Track the flow of private credit and the valuation agreements being reached. And stay alert to any geopolitical or regulatory developments that could introduce friction. The catalyst is real, but the path to a completed deal is rarely straightforward.